Form 4: Ekso Bionics Director Deborah Lafer Scher Reports Acquisition of Restricted Stock Units

Sentiment:

Statement of Changes in Beneficial Ownership


Director Deborah Lafer Scher reports acquisition of 78,217 restricted stock units (RSUs) in Ekso Bionics Holdings, Inc. following the company's annual meeting.

Summary

  • On June 6, 2024, Deborah Lafer Scher, a director of Ekso Bionics Holdings, Inc., acquired 78,217 restricted stock units (RSUs).
  • The RSUs were granted as part of an automatic annual non-employee director grant provision approved by the Company's Board of Directors on April 13, 2021.
  • Each RSU represents the economic equivalent of one share of EKSO common stock and will be settled in shares upon vesting.
  • The RSUs are scheduled to vest and settle at the earlier of the date of the next Annual Meeting of Stockholders or the one-year anniversary of the Grant Date.
  • Following the transaction, Scher beneficially owns 78,217 unvested RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices, aligning interests with shareholders.

Positives

  • The grant of RSUs to a director aligns their interests with those of the shareholders.
  • The vesting schedule encourages continued service and contribution to the company.

Future Outlook

The RSUs are scheduled to vest and settle at the earlier of the date of the next Annual Meeting of Stockholders or the one-year anniversary of the Grant Date.

Industry Context

This filing is a routine disclosure related to director compensation and is typical for publicly traded companies.

Comparison to Industry Standards

  • Director compensation packages often include equity-based awards like RSUs to align director interests with shareholder value.
  • The vesting schedule of one year or until the next annual meeting is a common practice.

Stakeholder Impact

  • The grant of RSUs aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

DateDescription
2021-04-13Date the Company's Board of Directors approved the automatic annual non-employee director grant provision.
2024-06-06Date of the transaction and the Issuer's 2024 Annual Meeting of Stockholders (the 'Grant Date').
2024-06-26Date of signature of the report by Attorney-in-Fact.

Keywords

EKSO BIONICS, Director, RSUs, Restricted Stock Units, Beneficial Ownership, Form 4, Deborah Lafer Scher

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.